NDAORALCAPSULEPriority Review
Approved
Nov 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
ANCOBON (flucytosine) by Bausch + Lomb. Approved for nucleoside analog antifungal [epc]. First approved in 1971.
Drug data last refreshed 21h ago
Mechanism of Action
Pharmacologic Class:
Nucleoside Analog Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Started Jul 2026
428 enrolled
Talaromycosis
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
Started Sep 2013
6 enrolled
Cryptococcal Infection Disseminated
Trial of TG4023 Combined With Flucytosine in Liver Tumors
Started Sep 2009
16 enrolled
Hepatocellular Carcinoma
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
400 enrolled
Meningitis, CryptococcalHIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
64 enrolled
Meningitis, CryptococcalHIV Infections
Worked on ANCOBON at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.